Publications by authors named "J L Dasseux"
Objective: CER-001 is an HDL mimetic that has been tested in different pathological conditions, but never with LCAT deficiency. This study was designed to investigate whether the absence of LCAT affects the catabolic fate of CER-001, and to evaluate the effects of CER-001 on kidney disease associated with LCAT deficiency.
Methods: Lcat and wild-type mice received CER-001 (2.
Article Synopsis
- - This clinical trial assessed the effectiveness of the HDL mimetic CER-001 in patients with very low levels of HDL cholesterol, aiming to see if it could help reduce atherosclerosis as previous trials had not shown results in patients with normal HDL levels.
- - 30 patients with familial hypoalphalipoproteinemia were treated with either CER-001 or a placebo over 24 weeks, with evaluations using advanced imaging techniques to measure changes in artery wall size and inflammation.
- - Results showed no significant difference in vessel wall size or inflammation between the treatment and placebo groups after 24 weeks, indicating that CER-001 did not provide the expected benefits in this specific patient population.
Effect of Serial Infusions of CER-001, a Pre-β High-Density Lipoprotein Mimetic, on Coronary Atherosclerosis in Patients Following Acute Coronary Syndromes in the CER-001 Atherosclerosis Regression Acute Coronary Syndrome Trial: A Randomized Clinical Trial.
JAMA Cardiol
September 2018
Article Synopsis
- CER-001 is an engineered HDL mimetic showing promise in reducing cholesterol and vascular inflammation, with a previous study indicating potential plaque regression in patients with high coronary plaque burden.
- The objective of the latest study was to assess the effect of CER-001 infusions on coronary atherosclerosis progression in patients already on statins.
- Conducted as a double-blind trial, 272 participants received either CER-001 or placebo over 10 weeks, focusing on changes in atheroma volume and overall safety.
The physiological role(s) of mammalian plasma lipoproteins is to transport hydrophobic molecules (primarily cholesterol and triacylglycerols) to their respective destinations. Lipoproteins have also been studied as drug-delivery agents due to their advantageous payload capacity, long residence time in the circulation and biocompatibility. The purpose of this review is to briefly discuss current findings with the focus on each type of formulation's potential for clinical applications.
View Article and Find Full Text PDFBackground: CER-001 is an engineered pre-beta high-density lipoprotein (HDL) mimetic, which rapidly mobilizes cholesterol. Infusion of CER-001 3 mg/kg exhibited a potentially favorable effect on plaque burden in the CHI-SQUARE (Can HDL Infusions Significantly Quicken Atherosclerosis Regression) study. Since baseline atheroma burden has been shown as a determinant for the efficacy of HDL infusions, the degree of baseline atheroma burden might influence the effect of CER-001.
View Article and Find Full Text PDF